Interestingly, however, treating tumor-bearing KPC mice with the JAK inhibitor AZD1480 led to a significant decrease in cancer cell proliferation and tumor growth as well as a significant increase in collagen deposition; It was also apparent that AZD1480-treated tumors had increased levels of αSMA, suggesting that JAK inhibition may promote a shift from an iCAF phenotype toward a myCAF-like state (Biffi et al., 2019). Here, ACTA1 is linked to cancer.